Selonsertib in Adults With Pulmonary Arterial Hypertension

Completed · Phase 2 · Has a placebo group

Conditions studied: Pulmonary Arterial Hypertension

In brief

The primary objective of this study is to evaluate the effect of selonsertib (GS-4997) on pulmonary vascular resistance (PVR), as measured by right heart catheterization (RHC) in adults with pulmonary arterial hypertension (PAH). The study will consist of a 24-week placebo-controlled treatment period and a long-term selonsertib treatment period. Participants completing the 24-week placebo-controlled period will be eligible to receive active treatment with selonsertib in the long-term treatment period.

Key facts

Study ID
NCT02234141
Run by
Gilead Sciences
People needed
151
Starts
2014-11-01
Expected to finish
2016-12-01
Last updated by the study team
2019-04-10

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.